Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice.

Chiu-Hsiang Connie Liao,Nilay Bakoglu,Emine Cesmecioglu,Matthew Hanna,Fresia Pareja,Hannah Y Wen,Timothy M D'Alfonso,Edi Brogi,Yukako Yagi,Dara S Ross
{"title":"Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice.","authors":"Chiu-Hsiang Connie Liao,Nilay Bakoglu,Emine Cesmecioglu,Matthew Hanna,Fresia Pareja,Hannah Y Wen,Timothy M D'Alfonso,Edi Brogi,Yukako Yagi,Dara S Ross","doi":"10.3389/pore.2024.1611826","DOIUrl":null,"url":null,"abstract":"Human epidermal growth factor receptor 2 (HER2) gene amplification and subsequent protein overexpression is a strong prognostic and predictive biomarker in invasive breast carcinoma (IBC). ASCO/CAP recommended tests for HER2 assessment include immunohistochemistry (IHC) and/or in situ hybridization (ISH). Accurate HER2 IHC scoring (0, 1+, 2+, 3+) is key for appropriate classification and treatment of IBC. HER2-targeted therapies, including anti-HER2 monoclonal antibodies and antibody drug conjugates (ADC), have revolutionized the treatment of HER2-positive IBC. Recently, ADC have also been approved for treatment of HER2-low (IHC 1+, IHC 2+/ISH-) advanced breast carcinoma, making a distinction between IHC 0 and 1+ crucial. In this focused study, 32 IBC with HER2 IHC scores from 0 to 3+ and HER2 FISH results formed a calibration dataset, and 77 IBC with HER2 IHC score 2+ and paired FISH results (27 amplified, 50 non-amplified) formed a validation dataset. H&E and HER2 IHC whole slide images (WSI) were scanned. Regions of interest were manually annotated and IHC scores generated by the software QuantCenter (MembraneQuant application) by 3DHISTECH Ltd. (Budapest, Hungary) and compared to the microscopic IHC score. H-scores [(3×%IHC3+) +(2×%IHC2+) +(1×%IHC1+)] were calculated for semi-automated (MembraneQuant) analysis. Concordance between microscopic IHC scoring and 3DHISTECH MembraneQuant semi-automated scoring in the calibration dataset showed a Kappa value of 0.77 (standard error 0.09). Microscopic IHC and MembraneQuant image analysis for the detection of HER2 amplification yielded a sensitivity of 100% for both and a specificity of 56% and 61%, respectively. In the validation set of IHC 2+ cases, only 13 of 77 cases (17%) had discordant results between microscopic and MembraneQuant images, and various artifacts limiting the interpretation of HER2 IHC, including cytoplasmic/granular staining and crush artifact were noted. Semi-automated analysis using WSI and microscopic evaluation yielded similar HER2 IHC scores, demonstrating the potential utility of this tool for interpretation in clinical practice and subsequent accurate treatment. In this study, it was shown that semi-automatic HER2 IHC interpretation provides an objective approach to a test known to be quite subjective.","PeriodicalId":19734,"journal":{"name":"Pathology Oncology Research","volume":"31 1","pages":"1611826"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology Oncology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/pore.2024.1611826","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Human epidermal growth factor receptor 2 (HER2) gene amplification and subsequent protein overexpression is a strong prognostic and predictive biomarker in invasive breast carcinoma (IBC). ASCO/CAP recommended tests for HER2 assessment include immunohistochemistry (IHC) and/or in situ hybridization (ISH). Accurate HER2 IHC scoring (0, 1+, 2+, 3+) is key for appropriate classification and treatment of IBC. HER2-targeted therapies, including anti-HER2 monoclonal antibodies and antibody drug conjugates (ADC), have revolutionized the treatment of HER2-positive IBC. Recently, ADC have also been approved for treatment of HER2-low (IHC 1+, IHC 2+/ISH-) advanced breast carcinoma, making a distinction between IHC 0 and 1+ crucial. In this focused study, 32 IBC with HER2 IHC scores from 0 to 3+ and HER2 FISH results formed a calibration dataset, and 77 IBC with HER2 IHC score 2+ and paired FISH results (27 amplified, 50 non-amplified) formed a validation dataset. H&E and HER2 IHC whole slide images (WSI) were scanned. Regions of interest were manually annotated and IHC scores generated by the software QuantCenter (MembraneQuant application) by 3DHISTECH Ltd. (Budapest, Hungary) and compared to the microscopic IHC score. H-scores [(3×%IHC3+) +(2×%IHC2+) +(1×%IHC1+)] were calculated for semi-automated (MembraneQuant) analysis. Concordance between microscopic IHC scoring and 3DHISTECH MembraneQuant semi-automated scoring in the calibration dataset showed a Kappa value of 0.77 (standard error 0.09). Microscopic IHC and MembraneQuant image analysis for the detection of HER2 amplification yielded a sensitivity of 100% for both and a specificity of 56% and 61%, respectively. In the validation set of IHC 2+ cases, only 13 of 77 cases (17%) had discordant results between microscopic and MembraneQuant images, and various artifacts limiting the interpretation of HER2 IHC, including cytoplasmic/granular staining and crush artifact were noted. Semi-automated analysis using WSI and microscopic evaluation yielded similar HER2 IHC scores, demonstrating the potential utility of this tool for interpretation in clinical practice and subsequent accurate treatment. In this study, it was shown that semi-automatic HER2 IHC interpretation provides an objective approach to a test known to be quite subjective.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用全切片图像对浸润性乳腺癌中的 HER2 免疫组化进行半自动分析:在临床实践中的实用解释。
人表皮生长因子受体 2(HER2)基因扩增和随后的蛋白过表达是浸润性乳腺癌(IBC)的一个强有力的预后和预测性生物标志物。ASCO/CAP 推荐的 HER2 评估测试包括免疫组化 (IHC) 和/或原位杂交 (ISH)。准确的 HER2 IHC 评分(0、1+、2+、3+)是对 IBC 进行适当分类和治疗的关键。HER2 靶向疗法,包括抗 HER2 单克隆抗体和抗体药物共轭物(ADC),已经彻底改变了 HER2 阳性 IBC 的治疗方法。最近,ADC 也被批准用于治疗 HER2 低(IHC 1+、IHC 2+/ISH-)的晚期乳腺癌,这使得 IHC 0 和 1+ 之间的区别变得至关重要。在这项重点研究中,32 例 HER2 IHC 得分为 0 至 3+ 的 IBC 和 HER2 FISH 结果组成了校准数据集,77 例 HER2 IHC 得分为 2+ 的 IBC 和配对 FISH 结果(27 例扩增,50 例非扩增)组成了验证数据集。扫描 H&E 和 HER2 IHC 全玻片图像(WSI)。由 3DHISTECH Ltd.(匈牙利布达佩斯)开发的软件 QuantCenter(MembraneQuant 应用程序)人工标注感兴趣区并生成 IHC 评分。(匈牙利布达佩斯)的软件(MembraneQuant 应用程序)生成 IHC 分数,并与显微镜下的 IHC 分数进行比较。半自动(MembraneQuant)分析计算出 H 分数[(3×%IHC3+) +(2×%IHC2+) +(1×%IHC1+)]。在校准数据集中,显微镜 IHC 评分与 3DHISTECH MembraneQuant 半自动评分之间的一致性 Kappa 值为 0.77(标准误差为 0.09)。显微镜 IHC 和 MembraneQuant 图像分析检测 HER2 扩增的灵敏度均为 100%,特异性分别为 56% 和 61%。在IHC 2+病例验证集中,77个病例中只有13个(17%)的显微镜和MembraneQuant图像结果不一致,而且还发现了各种限制HER2 IHC解读的伪影,包括细胞质/粒状染色和挤压伪影。使用 WSI 和显微镜评估进行的半自动分析得出了相似的 HER2 IHC 评分,这证明了该工具在临床实践和后续准确治疗中的潜在解释作用。本研究表明,半自动 HER2 IHC 分析为众所周知的主观检验提供了一种客观的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Feasibility of indocyanine green (ICG) fluorescence in ex vivo pathological dissection of colorectal lymph nodes-a pilot study. Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice. G protein-coupled estrogen receptor 1 and collagen XVII endodomain expression in human cutaneous melanomas: can they serve as prognostic factors? Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1